Abstract

BackgroundSeveral tumour necrosis factor (TNF) based therapeutics have already been approved for human use and several others are emerging. Therefore, we determined the mRNA expression levels of the TNF superfamily ligands (TNFSF) – e.g. TNF-α, lymphotoxin (LT)-α, LT-β, Fas-L (CD95-L), TNF-related apoptosis-inducing ligand (TRAIL), TNF-related weak inducer of apoptosis (TWEAK), 4-1BBL, OX40-L (CD252) and amyloid precursor protein (APP) in healthy human and mouse solid organs.MethodsWe used quantitative real time-PCR to analyse mRNA expression levels of TNFSF ligands. Murine models of acute ischemic renal injury, chronic oxalate nephropathy, and immune complex glomerulonephritis were used. Renal injury was assessed by PAS staining, and infiltrating immune cells were analysed by immunohistochemistry. Data was analysed using non-parametric ANOVA (non-parametric; Kruskal-Wallis test).ResultsWe observed significant differences in the mRNA expression levels of TNFSF ligands in human and mouse solid organs. Furthermore, we determined their mRNA expressions during acute and chronic kidney injuries in mice. Our data demonstrate that the mRNA expression levels of TNFSF vary depending on the type of tissue injury – for example, acute ischemic renal injury, chronic crystalline nephropathy, and immune complex glomerulonephritis. In addition, we observed that mRNA expressions of TNFSF ligands are differentially regulated during the course of a transient ischemic renal injury (IRI) and chronic kidney modelling. We observed that TNF-α, LT-β, and 4-1BBL were significantly upregulated during the progression of IRI and crystal-induced chronic kidney disease (CKD), whereas only 4-1BBL and TNF-α were significantly upregulated and LT-β was significantly downregulated during the progression of immune complex glomerulonephritis. The mRNA expression of Fas-L was higher during IRI whereas it decreased in a time dependent manner during the progression of crystal-induced CKD.ConclusionWe conclude that the injury- and species-specific differences of TNFSF ligands must be considered in order to avoid the misinterpretation and wrong conclusions during data extrapolation between species.

Highlights

  • Several tumour necrosis factor (TNF) based therapeutics have already been approved for human use and several others are emerging

  • MRNA expressions of TNF superfamily ligands (TNFSF) ligands are variable in healthy human solid organs compared to spleen

  • TNF superfamily ligands mRNA expressions in murine acute kidney injury We further studied the changes in the mRNA expression of TNFSF ligands during transient injury using a murine model of ischemic renal injury (IRI)

Read more

Summary

Introduction

Several tumour necrosis factor (TNF) based therapeutics have already been approved for human use and several others are emerging. The TNFSF members are expressed widely and play major roles in immune responses, inflammation, cell homeostasis, and tissue repair [4, 5]. They contribute to disease pathogenesis, and are referred as “double-edged swords” [3]. In 1984, the homology between TNF and LT was unveiled when they were purified to homogeneity and their amino acid sequences were determined [9, 10] This initiated the hunt for more TNFlike proteins leading to the discovery of 19 TNFSF ligands until today [3]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call